SBIR/STTR Research Award
DEVELOPMENT OF DIGITAL SATIORX, A VERY LOW COST REMOTELY CONTROLLABLE DISPOSABLE MICRONEEDLE TRANSDERMAL DRUG DELIVERY DEVICE ABLE TO DELIVER ANY LIQUID FDA APPROVED TRANSDERMAL DRUG
Award amount
$3,500,000Program and phase
SBIR · Phase II – Direct to Phase IIAward year
2023Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Advanced Research Projects Agency for Health
- Recipient company
- SATIO INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- H8WFVFLRQYN3
- Solicitation number
- 75N91023R00041
- Topic code
- AH02
Research abstract
The project plans to develop Digital SatioRx, a very low cost remotely controllable disposable microneedle transdermal drug delivery device able to deliver any liquid FDA-approved transdermal drug. Digital SatioRx's telemedicine-enabled (EHR-integrated), remotely activated, disposable design and unique delivery system will minimize infection risk and ensure administration of a reproducible drug dose to any patient in seconds. It will allow providers to ensure compliance while reducing costs and inconvenience for patients. Design features from other Satio telemedicine devices and manually operated transdermal delivery devices will guide final design.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.